CLIMB BIO, INC. Accrued Liabilities, Current
CLIMB BIO, INC. (CLYM) had Accrued Liabilities, Current of $6.10 million as of 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2025-05-14
- 2025-03-31: Accrued Liabilities, Current $6.10M.
- 2024-12-31: Accrued Liabilities, Current $4.07M.
- 2024-09-30: Accrued Liabilities, Current $3.04M.
- 2024-06-30: Accrued Liabilities, Current $2.95M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2025-03-31 | $6.10M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $4.07M 10-Q · filed 2025-05-14 | |
| 2024-09-30 | $3.04M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $2.95M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $2.64M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $2.43M 10-K · filed 2025-03-25 | |
| 2023-09-30 | $1.76M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $2.25M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $3.59M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $5.05M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $4.43M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $6.07M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $5.48M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $4.63M 10-K · filed 2023-03-06 | $4.59M 10-K · filed 2022-03-07 |
| 2021-09-30 | $2.98M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $3.63M 10-Q · filed 2021-09-13 | |
| 2020-12-31 | $1.22M 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |